Unigene Laboratories Inc. (UGNE) Profile

Profile for Unigene Laboratories Inc.  (UGNE) 
$ 0.60   0.05 (+9.09%) Volume: 71.3 k 2:38 PM EST Feb 10, 2012
Business Description:
Unigene Laboratories, Inc. focuses on the research, production and delivery of small proteins, referred to as peptides, for medical use. It has a patented manufacturing technology for producing many peptides cost-effectively.
Address: 81 Fulton Street, Boonton, NJ, 07005
Telephone: (973) 265-1100 Website: www.unigene.com
Facsimile: (973) 227-6088 Email: N/A
Details
CEO: Mr. Ashleigh Palmer
Employees: 68 Market Cap: 56.83 m
Issue Type: CS
Auditor: Grant Thornton LLP
Last Audit: Unqualified
Indices: Drug Manufacturers - Other
Industry Classifications
Sector: Healthcare CIK: 0000352747
Industry: Drugs
Sub-Industry:    Drug Manufacturers - Other
NAICS: Medicinal and Botanical Manufacturing (325411)
SIC: Medicinal Chemicals And Botanical Products (2833)   

Tags for Unigene Laboratories Inc.

Research stocks or mutual funds related to Unigene Laboratories Inc. by keywords or tags. Find companies that have a similar focus to UGNE. The keywords below have been associated to UGNE by either user submission or electronic means.

email stock quotes stock trading end of day stock quotes investor relations company real time stock quote osteoporosis doctor stock investments osteoporosis prevention and treatment biotech conference ups stock quote online stock quote niche pharmaceutical financial results investment products calcium osteoporosis stock information live stock quote india stock quotes financial annual report msft stock quote financial statements annual report stock investment preventing osteoporosis japan stock quotes calcium for osteoporosis after hours stock quotes financial news analysis osteoporosis in women stock quote osteoporosis treatment pharmaceutical software effects of osteoporosis old stock quotes best stocks dfc stock quote stock alerts women osteoporosis financial report warrick pharmaceutical stock ticker symbol stock quote chart osteoporosis bone loss new osteoporosis treatment licensed products calcium and osteoporosis information on osteoporosis annual report printing investor relations data xom stock quote